Central glucagon-like peptide 1 receptor activation inhibits Toll-like receptor agonist-induced inflammation
Chi Kin Wong(Lunenfeld-Tanenbaum Research Institute), Daniel J. Drucker(University of Toronto), Brent A. McLean(Cogent (United Kingdom)), Rola Hammoud(University of Toronto), Randy J. Seeley(University of Michigan), Laurie L. Baggio(Sinai Health System), Theodore J. Brown(Mount Sinai Hospital), Julian M. Yabut(Lunenfeld-Tanenbaum Research Institute), Jacqueline A. Koehler(Lunenfeld-Tanenbaum Research Institute), Nikolaj Rittig(Steno Diabetes Centers)
Cited by 251
Related Papers
Joint international consensus statement for ending stigma of obesity
|Nature Medicine|2020|1.1k
The role of gut hormones in glucose homeostasis
|Journal of Clinical Investigation|2007|611
Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
|Endocrine Reviews|2014|602
Enhancing Incretin Action for the Treatment of Type 2 Diabetes
|Diabetes Care|2003|578
Neuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect
|Journal of Clinical Investigation|2014|396